Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria

The Original Article was published on 31 January 2017

Nature Communications 8 Article number:14193 (2017); Published 31 January 2017; Updated 6 Apr 2017

This Article contains errors in Figs. 1 and 8 that were introduced during the production process. The compound on the lower right side of Fig. 1 is labelled incorrectly and should be labelled ‘SC83288’. The correct version of Fig. 1 appears below as Fig. 1. In Fig. 8c, ‘SC83458 selected’ should read ‘SC81458 selected’ and in Fig. 8d ‘SC81758’ should read ‘SC81458’. The correct version of Fig. 8 appears below as Fig. 2.

Figure 1
figure1

Figure 2
figure2

Authors

Additional information

The online version of the original article can be found at 10.1038/ncomms14193

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pegoraro, S., Duffey, M., Otto, T. et al. Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun 8, 15273 (2017). https://doi.org/10.1038/ncomms15273

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing